Aspiration Technique-based Device for Preterm Labor (PREGNOLIA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05355649 |
Recruitment Status :
Recruiting
First Posted : May 2, 2022
Last Update Posted : May 2, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Premature birth (PTB, birth before 37 weeks of pregnancy) is a global, yet unsolved, problem. With a global amount of approximately 15 M babies born prematurely, PTB is the leading cause of perinatal morbidity and mortality in many countries. Furthermore, premature babies often have complicated medical problems, especially those born very early.
Some women spontaneously deliver prematurely without any symptom or sign of the imminent labor, whereas others present with symptoms of preterm labor (PTL). In the latter case, clinicians can intervene and treat the woman with tocolytics and antenatal corticosteroids in order to accelerate fetal lung maturation and reduce the risk of respiratory distress syndrome. However, one of the major challenges in the management of women presenting with symptoms of PTL is to distinguish between true and false PTL with the existing clinical methods (digital examination or transvaginal cervical length assessment). In fact, over 50% of the women presenting with PTL symptoms do not deliver prematurely and are still unnecessarily hospitalized and treated with corticosteroids as well as tocolytics, and only less than 10% of women give birth within 7 days of presentation. Unnecessary treatments and hospitalizations also result in increased health costs.
Thus, there is a need for more accurate methods and tools to evaluate the cervical maturation status as indication of imminent labor in order to avoid unnecessary hospital admissions and therapy.
Recently, cervical stiffness has been evaluated as more reliable tool for prediction of spontaneous preterm birth. Cervical stiffness can be evaluated using ultrasound by cervical elastography , but also by an aspiration technique-based method with a novel CE-marked device, the Pregnolia System.
Thus, the aims of this study are to evaluate:
- if the cervical stiffness measured with the Pregnolia System can differentiate between women with true PTL and those with false PTL,
- if the knowledge of cervical stiffness improves the detection of women at true risk of spontaneous preterm birth in combination or over state of the art (e.g. cervical length on TVUS).
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Preterm Labor Preterm Birth | Device: PREGNOLIA SYSTEM | Not Applicable |
Premature birth (PTB, birth before 37 weeks of pregnancy) is a global, yet unsolved, problem. With a global amount of approximately 15 M babies born prematurely, PTB is the leading cause of perinatal morbidity and mortality in many countries. Furthermore, premature babies often have complicated medical problems, especially those born very early.
Some women spontaneously deliver prematurely without any symptom or sign of the imminent labor, whereas others present with symptoms of preterm labor (PTL). In the latter case, clinicians can intervene and treat the woman with tocolytics and antenatal corticosteroids in order to accelerate fetal lung maturation and reduce the risk of respiratory distress syndrome. However, one of the major challenges in the management of women presenting with symptoms of PTL is to distinguish between true and false PTL with the existing clinical methods (digital examination or transvaginal cervical length assessment). In fact, over 50% of the women presenting with PTL symptoms do not deliver prematurely and are still unnecessarily hospitalized and treated with corticosteroids as well as tocolytics, and only less than 10% of women give birth within 7 days of presentation. Unnecessary treatments and hospitalizations also result in increased health costs.
Thus, there is a need for more accurate methods and tools to evaluate the cervical maturation status as indication of imminent labor in order to avoid unnecessary hospital admissions and therapy.
Recently, cervical stiffness has been evaluated as more reliable tool for prediction of spontaneous preterm birth. Cervical stiffness can be evaluated using ultrasound by cervical elastography , but also by an aspiration technique-based method with a novel CE-marked device, the Pregnolia System.
Thus, the aims of this study are to evaluate:
- if the cervical stiffness measured with the Pregnolia System can differentiate between women with true PTL and those with false PTL,
- if the knowledge of cervical stiffness improves the detection of women at true risk of spontaneous preterm birth in combination or over state of the art (e.g. cervical length on TVUS).
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | PREGNOLIA SYSTEM |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Impact of a New Aspiration Technique-based Device for Assessment of Cervical Stiffness in Pregnant Women With Symptoms of Preterm Labour |
Actual Study Start Date : | April 8, 2022 |
Estimated Primary Completion Date : | September 1, 2022 |
Estimated Study Completion Date : | December 1, 2022 |
Arm | Intervention/treatment |
---|---|
PREGNOLIA TEST
Women at the time of triage will be tested with TVU CL (transvaginal ultrasound cervical length) and with the PREGNOLIA system
|
Device: PREGNOLIA SYSTEM
The Pregnolia System is composed of two products: an active device (Pregnolia Control Unit) and a single-use sterile probe (Pregnolia Probe). The intended use of the Pregnolia System is to provide information about the mechanical properties of the uterine cervix by assessing the tissue stiffness through a proxy parameter (the closing pressure, denominated CSI, or Cervical Stiffness Index, in mbar). The Pregnolia System is intended to be used in conjunction with the information obtained from the clinical evaluation of the patient and in addition to other standard examinations. |
- Value of the system in women with symptoms of preterm labor [ Time Frame: up to 34 weeks ]detection rate of PREGNOLIA system in women with symptoms of preterm labor (sensitivity, specificity, detection rate).
- Birth outcomes [ Time Frame: up to 34 weeks ]Correlation between the system of the results and birth outcome (gestational age at birth, time to delivery, mode of delivery)
- Comparison between pregnolia system and cevical length [ Time Frame: up to 34 weeks ]Detection rate of the two systems
- the change of the calcaneus stiffness index (CSI) at triage and discharge [ Time Frame: up to 34 weeks ]to determine the change of the CSI at triage and discharge

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
Sexes Eligible for Study: | Female |
Gender Based Eligibility: | Yes |
Gender Eligibility Description: | pregnant women |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Singleton gestations with symptoms of preterm labor
- Gestational age between 24 and 33 weeks
- Maternal age ≥18 years
Exclusion Criteria:
- Cervical dilatation ≥ 3 cm;
- Rupture of membranes;
- Cerclage or pessary in place;
- Severe vaginal bleeding;

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05355649
Contact: Gabriele Saccone, md | 0817461111 | gabriele.saccone.1990@gmail.com |
Italy | |
Gabriele Saccone | Recruiting |
Naples, Italy, 80100 | |
Contact: Gabriele Saccone 0817461111 gabriele.saccone.1990@gmail.com |
Principal Investigator: | Gabriele Saccone, md | federico ii |
Responsible Party: | Gabriele Saccone, Principal investigator, Federico II University |
ClinicalTrials.gov Identifier: | NCT05355649 |
Other Study ID Numbers: |
VanvFedII |
First Posted: | May 2, 2022 Key Record Dates |
Last Update Posted: | May 2, 2022 |
Last Verified: | April 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Plan Description: | not planned yet |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Premature Birth Obstetric Labor, Premature Obstetric Labor Complications Pregnancy Complications |